Navigation Links
invivodata Offers Complimentary PRO Gap Analysis
Date:3/24/2010

evelop PRO instruments that are “fit for purpose” for specific program objectives and to integrate ePRO seamlessly into their clinical operations. For additional information and to register for PROficiency 2010, please visit invivodata.com/proficiency2010.

"invivodata’s PRO Consulting scientists have long contributed to and tracked the regulations and guidance surrounding patient-reported data collection in clinical research," said Dr. Jean Paty, invivodata Co-founder and Vice President of Scientific, Quality, and Regulatory Affairs. "We are pleased to offer the PRO Gap Analysis and share our expertise with clinical researchers as they work to understand the new FDA Guidance and make key decisions about their PRO strategies in global clinical development programs."
To request a complimentary PRO Gap Analysis teleconference, please visit invivodata.com/pro-gap-analysis.


About invivodata inc.
invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consul
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. invivodata and PRO Consulting to Present at International Industry Events
2. invivodata Announces ePROficiency 2009 Web Seminar Series
3. Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development
4. invivodata Opens Registration for 3rd Annual Patient Reported Outcomes Conference
5. INC Research and invivodata Announce ePRO Partnership
6. New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
7. Radio wave cooling offers new twist on laser cooling
8. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
9. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
10. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
11. HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... Arlington, Massachusetts (PRWEB) October 22, 2014 ... recently announced the release of a new infographic, ... was to create a beautifully designed, easy to follow ... Ebola's transmission, areas of outbreak, symptoms and prevention. , ... have discovered that the 2014 Ebola outbreak represents not ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... of Darmstadt, Germany, has initiated a global Phase 3 ... with hormone receptor-positive, locally advanced, recurrent or metastatic breast ... developed by Merck KGaA under a license agreement with ...
... , , , , SINGAPORE, June 22 ... The EU,s commitment to achieve a reduction in CO2 emissions by ... of a target of 5.75 percent bio-fuels of all transportation fuel ... States is a smaller market, it is witnessing rapid growth in ...
... BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. ... will be presenting a scientific poster describing L-DOS47 analytical ... Pharmaceutical Scientists ("AAPS") National Biotechnology Conference, which runs from ... and Trade Center in Seattle, Washington. , ...
Cached Biology Technology:Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 4Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 3Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 4Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 2Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 3Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 4Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 5
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... University paleobiologist Gregory M. Erickson sliced up some ... an international team of scientists identify a new ... only subtle similarities, the FSU researcher determined that ... North America's hulking Tyrannosaurus rex. , Make that ...
... the once almost universally fatal childhood cancer acute lymphoblastic ... future, thanks to improvements in diagnosis and treatment over ... Jude Children's Research Hospital. Almost 4,000 cases of ALL ... two-thirds of which are in children and adolescents, making ...
... and Geoff Garnett (of Imperial College London) suggests that ... controlled through antiretroviral drugs alone, even if universal access ... the open-access international medical journal PLoS Medicine, without additional ... about safe sex, access to drugs is likely to ...
Cached Biology News:FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 2FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 3St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Access to antiretrovirals unlikely to reduce HIV infection rates 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: